NCT04830371已完成2 期
A Phase II/III, Multicenter, Observer-Blinded, Randomized, Non-inferiority and Safety Study of Typhoid Conjugate Vaccine (EuTCV) Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 444
- 试验地点
- 2
- 主要终点
- Proportion of Solicited local and systemic AEs
研究概览
简要总结
This is an observer-blinded, comparative, single dose, clinical phase II/III study to assess the immunogenicity and safety of EuTCV compared to Typhoid conjugate vaccine in healthy Filipino participants aged 6 months to 45 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 6 Months 至 45 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy participants ≥6 months and ≤45 years of age at enrolment
- •Participants/Parents/Legally Authorized Representative(LAR) willing to give written informed consent/assent to participate in the trial
- •Participants/Parents/LAR willing to follow the study procedures of the study and available for the entire duration of the study
- •Participants who are healthy as determined by medical history, with no clinically significant abnormalities in clinical examination and laboratory tests
- •Female participants must have a negative serum (at Screening) and negative urinary (at Day 1) pregnancy test and agree to use 2 methods of contraception from dosing until 90 days after vaccination.
排除标准
- •Participants/Parents/LAR unwilling to give his/her consent/assent to participate in the trial
- •Participants concomitantly enrolled or scheduled to be enrolled in another trial
- •Children and infants with a congenital abnormality
- •Known history of immune function disorders including immunodeficiency disease, or chronic use of systemic steroids, cytotoxic or other immunosuppressive drugs
- •Pregnant, lactating women or women of childbearing age not using a reliable method of contraception
- •History of uncontrolled coagulopathy or blood disorders
- •Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the trial objectives
- •History of alcohol or substance abuse
结局指标
主要结局
Proportion of Solicited local and systemic AEs
时间窗: 7 days after vaccination
Seroconversion rate
时间窗: 4 weeks after vaccination of EuTCV (pooled of 3 batches)/Typbar-TCV compared to baseline
Proportion of unsolicited AEs
时间窗: within 28 days after vaccination
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
3 期
A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerGastric CancerNCT04139135Shanghai Henlius Biotech642
进行中（未招募）
3 期
A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal CancerGastric or Gastroesophageal Junction CancerNCT04950322Suzhou Suncadia Biopharmaceuticals Co., Ltd.737
招募中
2 期
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)Metastatic Colorectal CancerNCT04547166Shanghai Henlius Biotech568
终止
2 期
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb SpasticitySpasticityNCT04099667Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC40
Unknown
3 期
Clinical Trial to Evaluate the Efficacy and Safety of Adhesion Barrier Mediclore Versus no Treatment in Patients With Total ThyroidectomyPatients With Thyroidectomy (Scheduled)NCT02940210CGBio Inc.172